Related Experiment Videos
Nonalcoholic steatohepatitis: clinicopathological profile
D N Amarapurkar1, A D Amarapurkar
1Bombay Hospital and Medical Research Centre.
The Journal of the Association of Physicians of India
|March 7, 2001
Summary
Nonalcoholic steatohepatitis (NASH) affects over 6% of chronic liver disease patients, presenting with elevated enzymes and risk factors like obesity and diabetes. Early diagnosis is crucial as NASH can progress to fibrosis and cirrhosis.
Area of Science:
- Hepatology
- Gastroenterology
- Internal Medicine
Background:
- Nonalcoholic steatohepatitis (NASH) is a significant cause of chronic liver disease.
- It is characterized by hepatic steatosis, inflammation, and hepatocyte injury.
- NASH can lead to progressive liver damage, including fibrosis and cirrhosis.
Purpose of the Study:
- To investigate the clinicopathological spectrum of nonalcoholic steatohepatitis (NASH).
- To identify the prevalence and risk factors associated with NASH in patients with chronic liver disease.
Main Methods:
- Evaluation of 210 patients with chronic liver disease.
- Inclusion of detailed history, clinical examination, laboratory investigations, radiological findings, and liver biopsy when feasible.
- Analysis of demographic data, presenting symptoms, and risk factors.
Main Results:
- NASH was diagnosed in 13 patients (6.19%) with a mean age of 55.4 years.
- Common risk factors included diabetes (4/13), obesity (4/13), hyperlipidemia (3/13), and steroid treatment (2/13).
- Liver biopsy revealed steatosis with inflammation in all NASH patients, with two showing fibrosis and one cirrhosis.
Conclusions:
- Nonalcoholic steatohepatitis (NASH) is a critical form of chronic liver disease.
- Clinical features include hepatomegaly and elevated liver enzymes.
- Timely diagnosis is essential to prevent progression to advanced liver disease such as fibrosis and cirrhosis.